The (TTTA)n polymorphism in intron 4 of CYP19 and the polycystic ovary syndrome risk in a Chinese population

Molecular Biology Reports

Volumn 40, Issue 8, 2013, Pages 5041-5047

  Xu, P ^a   Zhang, X L ^a   Xie, G B ^a   Zhang, C W ^a   Shen, S M ^a   Zhang, X X ^a   Cao, Y X ^b   Wang, W J ^c   Che, Y N ^a   Xia, Y J ^a   Wu, X K ^d   Yi, L ^a   Gao, Q ^a   Wang, Y ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

(TTTA) n; CYP19; Polycystic ovary syndrome; Polymorphism

Indexed keywords

ADENINE; AROMATASE; DNA; DNA FRAGMENT; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE; THYMINE;

ADULT; ALLELE; AMINO ACID SEQUENCE; ARTICLE; BODY MASS; CAPILLARY ELECTROPHORESIS; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; CYP19 GENE; DNA POLYMORPHISM; ESTRADIOL BLOOD LEVEL; FEMALE; FLUORESCENCE; FOLLITROPIN BLOOD LEVEL; GENE; GENE DELETION; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTRON; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SHORT TANDEM REPEAT; TESTOSTERONE BLOOD LEVEL;

EID: 84881184380     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2605-4     Document Type: Article

References (25)

1. Qiao J (2008) Prevalence of polycystic ovary syndrome in China. Second international symposium on PCOS, Haerbing, China, 174-175
2. Diamanti-Kandarakis E, Piperi C, Spina J, Argyrakopoulou G, Papanastasiou L, Bergiele A, Panidis D (2006) Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens) 5(1):17-34
3. Richard SL, Rhonda BL, Deborah D, Steve CW, Andrea D (2002) Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 87(5):2128-2133
4. Shah NA, Antoine HJ, Pall M, Taylor KD, Azziz R, Goodarzi MO (2008) Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J Clin Endocrinol Metab 93(5):1939-1945. doi: 10.1210/jc.2008-0038
5. Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I (2003) Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab 88(12):5976-5980
6. Mendelson CR, Means GD, Mahendroo MS, Corbin CJ, Steinkampf MP, Grahamlorence S, Simpson ER (1990) Use of molecular probes to study regulation of aromatase cytochrome P-450. Biol Reprod 42(1):1-10
7. Blankenstein MA, van de Ven J, Maitimu-Smeele I, Donker GH, de Jong PC, Daroszewski J, Szymczak J, Milewicz A, Thijssen JHH (1999) Intratumoral levels of estrogens in breast cancer. J Steroid Biochem 69(1-6):293-297
8. Jin JL, Sun J, Ge HJ, Cao YX, Wu XK, Liang FJ, Sun HX, Ke L, Yi L, Wu ZW, Wang Y (2009) Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women. BMC Med Genet 10:139. doi: 10.1186/1471-2350-10-139
9. Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Karesen R, Kristensen T, Borresen-Dale AL (2000) Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 19(10):1329-1333. doi: 10.1038/sj.onc.1203425
10. Czajka-Oraniec I, Zgliczynski W, Kurylowicz A, Mikula M, Ostrowski J (2008) Association between gynecomastia and aromatase (CYP19) polymorphisms. Eur J Endocrinol 158(5):721-727. doi: 10.1530/EJE-07-0556
11. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19-25
12. Jahanfar SEJ, Warren P, Seppälä M, Nguyen TV (1995) A twin study of polycystic ovary syndrome. Fertil Steril 63(3):9
13. Kado NKJ, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Tsukamoto K, Hasegawa G, Nakamura N, Yoshikawa T, Honjo H (2002) Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Hum Reprod 17(4):6. doi: 10.1093/humrep/17.4.897
14. Stratakis CAVA, Brodie A, Kirschner LS, DeAtkine D, Lu Q, Yue W, Mitsiades CS, Flor AW, Chrousos GP (1998) The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab 83(4):10. doi: 10.1210/jc.83.4.1348
15. Haiman CA, Hankinson SE, Spiegelman D, De Vivo I, Colditz GA, Willett WC, Speizer FE, Hunter DJ (2000) A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 87(2):204-210
16. Kristensen VNAT, Lindblom A, Erikstein B, Magnus P, Børresen-Dale AL (1998) A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 8(1):5
17. Ahsan H, Whittemore AS, Chen Y, Senie RT, Hamilton SP, Wang Q, Gurvich I, Santella RM (2005) Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study. Breast Cancer Res 7(1):R71-R81. doi: 10.1186/bcr951
18. Thyagarajan BBM, Mink P, Folsom AR, Anderson KE, Oetting WS, Gross M (2004) CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. Cancer Lett 207(2):7
19. Healey CS, Dunning AM, Durocher F, Teare D, Pharoah PD, Luben RN, Easton DF, Ponder BA (2000) Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 21(2):189-193
20. Gennari L, Masi L, Merlotti D, Picariello L, Falchetti A, Tanini A, Mavilia C, Del Monte F, Gonnelli S, Lucani B, Gennari C, Brandi ML (2004) A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 89(6):2803-2810. doi: 10.1210/jc.2003-031342
21. Berstein LM, Imyanitov EN, Kovalevskij AJ, Maximov SJ, Vasilyev DA, Buslov KG, Sokolenko AP, Iyevleva AG, Chekmariova EV, Thijssen JHH (2004) CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. Cancer Lett 207(2):191-196. doi: 10.1016/j.canlet.2004.01.001
22. Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B, Sebastian S (2004) Organization of the human aromatase p450 (CYP19) gene. Semin Reprod Med 22(1):5-9. doi: 10.1055/s-2004-823022
23. Xita N, Chatzikyriakidou A, Stavrou I, Zois C, Georgiou I, Tsatsoulis A (2010) The (TTTA)n polymorphism of aromatase (CYP19) gene is associated with age at menarche. Hum Reprod 25(12):3129-3133. doi: 10.1093/humrep/deq276
24. Xita N, Lazaros L, Georgiou I, Tsatsoulis A (2010) CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype. Fertil Steril 94(1):250-254. doi: 10.1016/j.fertnstert.2009.01.147
25. Hao CF, Zhang N, Qu Q, Wang X, Gu HF, Chen ZJ (2010) Evaluation of the association between the CYP19 Tetranucleotide (TTTA)n polymorphism and polycystic ovarian syndrome (PCOS) in Han Chinese women. Neuro Endocrinol Lett 31(3):370-374